Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 8/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.39 |
| ▸ | KLK7 | P49862 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | UBE2N | P61088 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25421651 | 0.80 | ALDH1A1 (0.47) | HTR6L3MBTL1ALDH1A1LMNAPOLB | |
| SCHEMBL30461591 | 0.80 | ALDH1A1 (0.47) | HTR6L3MBTL1ALDH1A1LMNAPOLB | |
| SCHEMBL30461664 | 0.79 | ALDH1A1 (0.43) | HTR6L3MBTL1ALDH1A1KDM4EUBE2N | |
| SCHEMBL25419377 | 0.79 | ALDH1A1 (0.43) | HTR6L3MBTL1ALDH1A1KDM4EUBE2N | |
| SCHEMBL25422502 | 0.76 | HTR6 (0.40) | HTR6ACHEL3MBTL1MCOLN3KLK7 | |
| SCHEMBL30974647 | 0.74 | HTR6 (0.54) | HTR6ACHEKLK7KDM4EUBE2N | |
| SCHEMBL31543235 | 0.73 | HTR6 (0.48) | HTR6HTR1AKLK7KDM4EUBE2N | |
| SCHEMBL30372719 | 0.72 | HTR6 (0.49) | HTR6ACHEL3MBTL1KLK7KDM4E | |
| SCHEMBL30294963 | 0.71 | HTR6 (0.39) | HTR6ACHEHTR1AL3MBTL1MCOLN3 | |
| SCHEMBL30349338 | 0.71 | ACHE (0.42) | HTR6ACHEL3MBTL1MCOLN3KLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES INC | 2025-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | DYRK2, DYRK1A, DYRK1B | HTR6 521/4885ACHE 482/4885HTR1A 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.